Cystatin A, a Potential Common Link for Mutant Myocilin Causative Glaucoma
Open Access
- 15 May 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (5) , e36301
Abstract
Myocilin (MYOC) is a 504 aa secreted glycoprotein induced by stress factors in the trabecular meshwork tissue of the eye, where it was discovered. Mutations in MYOC are linked to glaucoma. The glaucoma phenotype of each of the different MYOC mutation varies, but all of them cause elevated intraocular pressure (IOP). In cells, forty percent of wild-type MYOC is cleaved by calpain II, a cysteine protease. This proteolytic process is inhibited by MYOC mutants. In this study, we investigated the molecular mechanisms by which MYOC mutants cause glaucoma. We constructed adenoviral vectors with variants Q368X, R342K, D380N, K423E, and overexpressed them in human trabecular meshwork cells. We analyzed expression profiles with Affymetrix U133Plus2 GeneChips using wild-type and null viruses as controls. Analysis of trabecular meshwork relevant mechanisms showed that the unfolded protein response (UPR) was the most affected. Search for individual candidate genes revealed that genes that have been historically connected to trabecular meshwork physiology and pathology were altered by the MYOC mutants. Some of those had known MYOC associations (MMP1, PDIA4, CALR, SFPR1) while others did not (EDN1, MGP, IGF1, TAC1). Some, were top-changed in only one mutant (LOXL1, CYP1B1, FBN1), others followed a mutant group pattern. Some of the genes were new (RAB39B, STC1, CXCL12, CSTA). In particular, one selected gene, the cysteine protease inhibitor cystatin A (CSTA), was commonly induced by all mutants and not by the wild-type. Subsequent functional analysis of the selected gene showed that CSTA was able to reduce wild-type MYOC cleavage in primary trabecular meshwork cells while an inactive mutated CSTA was not. These findings provide a new molecular understanding of the mechanisms of MYOC-causative glaucoma and reveal CSTA, a serum biomarker for cancer, as a potential biomarker and drug for the treatment of MYOC-induced glaucoma.Keywords
This publication has 75 references indexed in Scilit:
- Mutations in CSTA, Encoding Cystatin A, Underlie Exfoliative Ichthyosis and Reveal a Role for This Protease Inhibitor in Cell-Cell AdhesionThe American Journal of Human Genetics, 2011
- Stanniocalcin 2 Is a Negative Modulator of Store-Operated Calcium EntryMolecular and Cellular Biology, 2011
- Development of a Gene Therapy Virus with a Glucocorticoid-Inducible MMP1 for the Treatment of Steroid GlaucomaInvestigative Ophthalmology & Visual Science, 2010
- Mutations in the Small GTPase Gene RAB39B Are Responsible for X-linked Mental Retardation Associated with Autism, Epilepsy, and MacrocephalyThe American Journal of Human Genetics, 2010
- Functional Role of Proteolytic Processing of Recombinant Myocilin in Self-AggregationInvestigative Ophthalmology & Visual Science, 2010
- Individual molecular response to elevated intraocular pressure in perfused postmortem human eyesPhysiological Genomics, 2009
- Myocilin Is a Modulator of Wnt SignalingMolecular and Cellular Biology, 2009
- Evidence for a calcification process in the trabecular meshworkExperimental Eye Research, 2009
- Clinical Features Associated With an Asp380His Myocilin Mutation in a US Family With Primary Open-Angle GlaucomaAmerican Journal of Ophthalmology, 2007
- Myocilin-associated exosomes in human ocular samplesExperimental Eye Research, 2007